birth defects | GenomeWeb

birth defects

The company's new clinical laboratory will provide interim and backup services for its customers.

The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.

The four-year project aims to sequence about 800 kids and their parents to get a clearer idea of the genetic underpinnings of birth defects with unknown causes. 

The Suzhou, China-based laboratory will focus on neonatal testing and infectious diseases, with the potential to expand into cancer testing. 

NEW YORK (GenomeWeb News) – Researchers from Stephen Quake's laboratory at Stanford University have a published a method in Nature describing a way to noninvasively sequence a fetal genome and identify clinically relevant alleles without prior knowledge of paternal genetic data.

A new, $4 million per-year grant program will fund basic and translational studies of the genetic and molecular basis of congenital birth defects.

Quest, whose ClariSure test is based on a bacterial artificial chromosome array, is also considering adopting oligonucleotide array-based platforms sold by companies such as Affymetrix, Agilent Technologies, Illumina, and others.

BioArray Briefs

Premium

Quest Diagnostics, Centre for Proteomic and Genomic Research, SimuGen, Arrayit, Phalanx, Rosetta Biosoftware, Exiqon, Norgen Biotek, TcLand Expression, Genedata, GeneGo, Entelos, Integrated DNA Technologies, VH Bio, SciGene, Inter Medico

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.